1. Byrd, J.C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2013. Vol. 369, N 1. P. 32–42.
2. Byrd J.C. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia // N. Engl. J. Med. 2014. Vol. 371, N 3. P. 213–223.
3. Byrd, J.C. et al. Threeyear followup of treatmentnaive and previously treated patients with CLL and SLL receiving singleagent ibrutinib // Blood. 2015. Vol. 125, N 16. P. 2497–2506.
4. Moreno, C. et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in firstline treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, openlabel, phase 3 trial // Lancet Oncol. 2019. Vol. 20, N 1. P. 43–56.
5. Burger J.A. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia // N. Engl. J. Med. 2015. Vol. 373, N 25. P. 2425–2437.
6. Hallek M. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial // Lancet. 2010. Vol. 376, N 9747. P. 1164–1174.
7. Bruton O.C. et al. Absence of serum gamma globulins // AMA Am. J. Dis. Child. 1952. Vol. 84, N 5. P. 632–636.
8. Rawlings D.J. et al. Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice // Science. 1993. Vol. 261, N 5119. P. 358–361.
9. Tsukada S. et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human Xlinked agammaglobulinemia. 1993 // J. Immunol. 2012. Vol. 188, N 7. P. 2936–2947.
10. Rickert R.C., New insights into preBCR and BCR signalling with relevance to B cell malignancies // Nat. Rev. Immunol. 2013. Vol. 13, N 8. P. 578–591.
11. Singh J., Petter R.C., Kluge A.F. Targeted covalent drugs of the kinase family // Curr. Opin. Chem. Biol. 2010. Vol. 14, N 4. P. 475–480.
12. Buggy J.J., Elias L. Bruton tyrosine kinase (BTK) and its role in Bcell malignancy // Int. Rev. Immunol. 2012. Vol. 31, N 2. P. 119–132.
13. Wiestner A., Emerging role of kinasetargeted strategies in chronic lymphocytic leukemia // Blood. 2012. Vol. 120, N 24. P. 4684-4691.
14. Liu X. et al. Intracellular MHC class II molecules promote TLRtriggered innate immune responses by maintaining activation of the kinase Btk // Nat. Immunol. 2011. Vol. 12, N 5. P. 416–424.
15. Treon S.P. et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia // N. Engl. J. Med. 2012. Vol. 367, N 9. P. 826–833.
16. Shinners N.P. et al. Bruton’s tyrosine kinase mediates NFkappa B activation and B cell survival by B cellactivating factor receptor of the TNFR family // J. Immunol. 2007. Vol. 179, N 6. P. 3872–3880.
17. de Gorter D.J. et al. Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokinecontrolled B cell migration and homing // Immunity. 2007. Vol. 26, N 1. P. 93–104.
18. Packham G. et al. The outcome of Bcell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy // Haematologica. 2014. Vol. 99, N 7. P. 1138–1148.
19. Dal Porto J.M. et al. B cell antigen receptor signaling 101 // Mol. Immunol. 2004. Vol. 41, N 6–7. P. 599–613.
20. Deglesne P.A. et al. Survival response to Bcell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression // Cancer Res. 2006. Vol. 66, N 14. P. 7158–7166.
21. Bernal A. et al. Survival of leukemic B cells promoted by engagement of the antigen receptor // Blood. 2001. Vol. 98, N 10. P. 3050–3057.
22. Wodarz D. et al. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib // Blood. 2014. Vol. 123, N 26. P. 4132–4135.
23. Ponader S. et al. The Bruton tyrosine kinase inhibitor PCI32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo // Blood. 2012. Vol. 119, N 5. P. 1182–1189.
24. Boissard F. et al. Nurselike cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients // Blood Cancer J. 2015. Vol. 5, N 10. P. e355.
25. de Weers M. et al. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages // Eur. J. Immunol. 1993. Vol. 23, N 12. P. 3109–3114.
26. Honigberg L.A. et al. The Bruton tyrosine kinase inhibitor PCI32765 blocks Bcell activation and is efficacious in models of autoimmune disease and Bcell malignancy // Proc. Natl Acad. Sci. USA. 2010. Vol. 107, N 29. P. 13 075–13 080.
27. Byrd J.C. et al. Acalabrutinib (ACP196) in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2016. Vol. 374, N 4. P. 323–332.
28. Dubovsky J.A. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1selective pressure in T lymphocytes // Blood. 2013. Vol. 122, N 15. P. 2539–2549.
29. Wang A. et al. Ibrutinib targets mutantEGFR kinase with a distinct binding conformation // Oncotarget. 2016. Vol. 7, N 43. P. 69 760–69 769.
30. Levade M. et al. Ibrutinib treatment affects collagen and von Willebrand factordependent platelet functions // Blood. 2014. Vol. 124, N 26. P. 3991–3995.
31. Lanning B.R. et al. A road map to evaluate the proteomewide selectivity of covalent kinase inhibitors // Nat. Chem. Biol. 2014. Vol. 10, N 9. P. 760–767.
32. de Jong J. et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia // Cancer Chemother. Pharmacol. 2015. Vol. 75, N 5. P. 907–916.
33. Bernard S. et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse // Blood. 2015. Vol. 126, N 14. P. 1695–1698.